On October 12, 2022 Triumvira Immunologics ("Triumvira"), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, reported that Senior Management will participate in four upcoming healthcare investor conferences (Press release, Triumvira Immunologics, OCT 12, 2022, View Source [SID1234621966]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer Private Company Showcase: The Next Wave: presentation at 2:35 pm PT on Tuesday, October 18th and available for investor meetings
Bank of America Healthcare Life Sciences Private Company Conference: available for in-person investor meetings on Thursday, October 20th
Wells Fargo Private Biotech Symposium: available for virtual investor meetings on Wednesday, November 2nd
Stifel 2022 Healthcare Conference: presentation on Wednesday, November 16th at 9:10 am ET and available for investor meetings

On October 12, 2022 NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, reported the publication of its first paper describing the CosMx Spatial Molecular Imager’s (SMI) chemistry, reproducibility, and sensitivity, as well as the application of the technology to study non-small cell lung cancer and breast cancer samples in Nature Biotechnology (Press release, NanoString Technologies, OCT 12, 2022, View Source [SID1234621965]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The paper, entitled High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging, was led by Joseph Beechem, Ph.D., chief scientific officer, NanoString. The team profiled multi-omic data of RNAs and proteins at subcellular resolution using formalin-fixed paraffin-embedded non-small cell lung and breast cancer tissues. Over 18 distinct cell types, 10 unique tumor microenvironments, and 100 pairwise ligand-receptor interactions were discovered.

"CosMx SMI enables researchers to image intact tissue sections at unprecedented levels of cell number, spatial resolution, plex, and multi-analyte," said Dr. Beechem. "This technology allows researchers to discover completely new insights into how tissues function, in health and disease, accelerating the current revolution in spatial biology."

CosMx SMI is the newest product in the company’s industry-leading spatial analysis tools portfolio, joining the GeoMx Digital Spatial Profiler (DSP). The GeoMx DSP is a fully-automated spatial profiler with an installed base of more than 300 systems as of June 30, 2022. The GeoMx DSP allows multi-cellular analysis of all the genes in the transcriptome for both human and mouse applications; both platforms are also customizable for other species.

The CosMx SMI compliments GeoMx, extending experiments to single cell and subcellular resolution across the entire tissue section. In addition, both CosMx and GeoMx are compatible with the AtoMx Spatial Informatics Portal (SIP), a cloud-based informatics platform that will provide an integrated ecosystem with streamlined workflows to manage, analyze and share spatial biology data.

The commercial CosMx SMI instruments are expected to ship later this year. In the meantime, researchers can apply the power of SMI to their tissue samples through the SMI Technology Access Program service provided by NanoString. For more information, email [email protected].

To learn more about NanoString’s CosMx Spatial Molecular Imager, visit www.nanostring.com/CosMx

On October 12, 2022 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, reported that three data presentations will occur at the CHEST 2022 Annual Meeting which will be held live and in-person for the first time since 2019 (Press release, Biodesix, OCT 12, 2022, View Source [SID1234621964]). Presentations will include a sub-group analysis of data from the post-market, prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2 Test – ORACLE [NCT03766958]) demonstrating that the Nodify XL2 test has equivalent performance in identifying patients with benign nodules discovered through lung cancer screening programs, compared to those discovered incidentally through medical imaging for unrelated diagnostic purposes. This prospectively collected data reinforces the potential of the Nodify XL2 test to identify high-risk individuals participating in lung cancer screening who have a likely-benign lung nodule and can avoid an unnecessary invasive biopsy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"One out of four LDCT scans reveal a new lung nodule, most of which are benign. Determining which patients require a prompt biopsy and which can be monitored with routine surveillance is critical to the goal of optimal management of indeterminate pulmonary nodules."

Tweet this
"Last year, the United States Preventative Services Task Force (USPSTF) expanded the screening criteria, doubling the population eligible for low-dose computed tomography (LDCT) screening in the U.S. to an estimated 16 million people" said James Jett, MD, Co-Chief Medical Officer at Biodesix. "One out of four LDCT scans reveal a new lung nodule, most of which are benign. Determining which patients require a prompt biopsy and which can be monitored with routine surveillance is critical to the goal of optimal management of indeterminate pulmonary nodules."

The ORACLE Study Principal Investigator, Michael Pritchett, DO, MPH, Director, Chest Center of the Carolinas at FirstHealth and past President of the Society for Advanced Bronchoscopy, released this data based on the use of the Nodify XL2 test in a real-world clinical practice setting.

"As expected, the data shows that we can use biological information from patients’ blood as a complement to standard risk assessment methods to better stratify patients with lung nodules, possibly avoid invasive procedures on those that have benign nodules and focus on the patients who may benefit from interventions," said Dr. Pritchett.

Rapid Fire Oral Presentation, Monday, October 17, 1:30 PM, Exhibit Hall Rapid Area 4C:
Comparison of the Performance of a Blood-Based Integrated Classifier in Risk Stratifying Incidental and Screening-Detected Pulmonary Nodules.

Dr. Pritchett will present a sub-group analysis from the ORACLE study, which is evaluating healthcare providers utilizing the blood-based Nodify XL2 proteomic test to reduce the number of invasive procedures on benign lung nodules. The author reviewed the test’s ability to identify benign lung nodules from patients (n = 280) who had a newly identified, 8-30 mm lung nodule discovered incidentally (n = 211) or through a lung cancer screening program (n = 69). The results demonstrate that the Nodify XL2 test did not differ between the two populations, maintaining a high sensitivity and negative predictive value (NPV) as previously reported in the PANOPTIC clinical study (NCT01752114).

Oral Presentation, Monday, October 17, 1:30 PM, Convention Center Room 104DE:
Impact of the Nodify Biomarker Panel for Risk Stratification of Pulmonary Nodules at an Academic Medical Center.

Jonathan Kurman, MD, MBA, FCCP, Director of Interventional Pulmonology at the Medical College of Wisconsin and ORACLE study investigator, reviewed 110 patients with 8-30 mm lung nodules receiving Nodify Lung testing in his clinical practice to assess the reclassification rates from intermediate (5-65% probability of cancer [pCA]) into high (>65% pCA) or very low (<5% pCA) groups. In the oral presentation, Bailey Ray, MD from the Medical College of Wisconsin will present the results of this analysis demonstrating that approximately one-third of all patients were reclassified into the high or very low risk group, further informing diagnostic decisions through shared decision-making discussions with patients.

Rapid Fire Oral Presentation, Wednesday, October 19, 11:15 AM, Exhibit Hall Rapid Area 3A:
Impact of a Blood-Based Integrated Classifier to Reclassify Lung Nodule Risk Across Nodule Size Spectrum.

Dr. Kurman will present a sub-group analysis from the ORACLE study assessing the performance of the Nodify XL2 proteomic test in identifying benign lung nodules across nodule size groups: <10 mm (n = 92), 10-15 mm (n = 124), and >15 mm (n = 64). The results demonstrate that the performance of the test is similar across size groups with high sensitivity and NPV as previously reported in the PANOPTIC clinical study (NCT01752114), identifying patients who may benefit from CT surveillance independent of nodule size.

On October 12, 2022 Propanc Biopharma, Inc. (OTC Pink: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, reported that Mr. James Nathanielsz, Propanc’s Chief Executive Officer, will attend the 43rd Meeting of the European Organization of Research and Treatment of Cancer (EORTC), Pharmacology and Molecular Mechanisms (PAMM) group. Professor Perán, Propanc’s Lead Joint Researcher, will also be presenting at the annual EORTC-PAMM meeting to be held in Florence, Italy, December 15 – 17 (Press release, Propanc, OCT 12, 2022, View Source [SID1234621963]). Topics covered will be innovation and application of pharmacological knowledge to cancer drug discovery and development, with particular regard to innovative and advanced drugs and their mechanisms of action, pharmacometrics and clinical application in oncology. Professor Perán, supported by Mrs. Belén Toledo Cutillas MSc and Mr. Aitor González from Professor Perán’s laboratory at Jaén University will present findings on the anti-cancer effects of the Company’s lead product candidate, PRP, effects on the tumor microenvironment and upscaling of synthetic recombinant protein production for a backup clinical compound for PRP.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The EORTC is a prestigious and globally recognized organization with significant resources and outreach. Mr. Nathanielsz looks forward to attending the 43rd EORTC-PAMM meeting with Jaén and Granada Universities, as part of the Joint Research Collaboration Project. Propanc’s goal is to produce a non, toxic, long-term therapy for the treatment and prevention of metastatic cancer from solid tumors by targeting and eradicating cancer stem cells, and as an adjunct therapy to pre-treat resistant tumors.

"Attendance at the EORTC-PAMM meeting provides an exciting opportunity to meet with scientific experts and clinical researchers who are at the cutting edge of cancer drug development, which presents an opportunity to discuss recent scientific discoveries from our PRP, R&D project and its potential clinical applications as a pre-treatment with existing innovative cancer therapies," said Mr. Nathanielsz, Propanc’s Chief Executive Officer. "Professor Perán has uncovered how PRP treats and prevents metastatic cancer by targeting and eradicating cancer stem cells via differentiation (turning back), so they become benign and are no longer malignant, without affecting healthy cells. She is also investigating the effects of PRP on the tumor microenvironment, where resistant tumors become susceptible to standard therapies, post treatment with PRP. We are excited to present our research with Professor Perán as we investigate future clinical applications of PRP in controlled human studies."

The EORTC’s mission is to increase people’s survival and quality of life by testing new therapeutic strategies based on existing drugs, surgery and radiotherapy. The EORTC also helps develop new drugs and approaches in partnership with the pharmaceutical industry and in patients’ best interests. The EORTC research network consists of over 5,500 collaborators from all disciplines involved in cancer treatment and research in more than 930 institutions in 27 countries. Its research spans the entire spectrum from translational and preclinical research to large, prospective, multi-center, phase III clinical trials that evaluate new cancer therapies.

Propanc is currently undertaking two joint research and collaboration projects with the Universities of Jáen and Granada. The first project, POP1 (Proenzyme Optimization Project 1) Joint Research and Drug Discovery Program, is designed to produce a back clinical compound to PRP, which is targeting metastatic cancer from solid tumors. The second involves investigating the effects of proenzyme therapy and the impact on the tumor microenvironment, which is key to the development, invasion, metastatic spread and recurrence of solid tumors. This has potential implications for future clinical applications of PRP as a potential pre-treatment for resistant tumors. According to Emergen Research, the global metastatic cancer market is projected to be worth $111 Billion by 2027. Propanc is undertaking these challenging research projects in collaboration with the Universities of Jaén and Granada, led by Professors Perán and Juan Antonio Marchal MD, representing the Universities, respectively, and Dr Kenyon, MD, MB, ChB, Propanc’s Chief Scientific Officer.

PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine and skin cancers.

About the EORTC

As an independent, non-governmental, non-profit cancer research Organization established under the laws of Belgium, its mission is to coordinate and conduct international translational and clinical research to improve the standard of cancer treatment for patients.

EORTC aims ultimately to increase people’s survival and quality of life by testing new therapeutic strategies based on existing drugs, surgery, and radiotherapy. EORTC also helps develop new approaches with the pharmaceutical industry and in patients’ best interests.

In addition to independence, EORTC is recognized for scientific and methodological rigor bringing robust datasets to doctors and patients for therapeutic improvement. EORTC covers all disciplines to fight against cancer. EORTC research leaves no one behind and addresses all patients, including patients with rare tumors and specific patient populations.

About Professor Macarena Perán

Professor Macarena Perán graduated with a B. S. in Biology and a M.S. in Biochemistry and Molecular Biology in 1996 from the University of Málaga, Spain. She moved to the Neuroscience Department at Durham University, UK, where she was awarded with a Marie Curie Fellowship and graduated in 2000 with a Ph.D. She moved back to Spain and completed a postdoctoral program in the Faculty of Medicine at Granada University.

In 2005 and 2006 Macarena went to Bath University, UK, and was a short-term postdoctoral fellow in the Department of Biology & Biochemistry in Professor David Tosh’s laboratory, where she first studied the anti-cancer effects of proenzymes in collaboration with Propanc Biopharma Inc. Professor Perán is a Reader in Anatomy, University of Jaen, Spain and belongs to the Institute for Regenerative Medicine and Pathobiology (IBIMER).

On October 12, 2022 Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (Nasdaq: AADI), a commercial stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, reported a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors (Press release, Mirati, OCT 12, 2022, View Source [SID1234621962]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The primary objective of this multi-center, single-arm, open-label Phase 1/2 trial is to determine the optimal dose and recommended Phase 2 dose for the combination of adagrasib and nab-sirolimus in patients with KRASG12C – mutant solid tumors. In addition, the study will investigate the safety, tolerability and efficacy of adagrasib and nab-sirolimus in combination in patients both with and without prior exposure to a KRASG12C inhibitor. The trial will build on preclinical data showing enhanced anti-tumor efficacy with the combination of adagrasib and nab-sirolimus relative to either agent alone.

"We are pleased to collaborate with Aadi on this clinical study of adagrasib and nab-sirolimus. Our collaborative preclinical work has demonstrated that combinatorial mTOR and KRAS inhibition addresses key bypass and feedback pathways associated with either drug target and also results in enhanced efficacy in tumor models harboring KRASG12C mutations. We believe the data from this trial may improve patient outcomes," said Charles Baum, M.D., Ph.D., president, founder and head of research and development, Mirati Therapeutics, Inc. "This clinical collaboration is an example of how Mirati is aggressively advancing the study of adagrasib both as a monotherapy and in rational combinations as part of our expanding development portfolio to benefit people living with difficult-to-treat cancers."

"KRAS and mTOR are closely linked and key pathways in oncogenesis and resistance to treatment. This collaboration builds on strong preclinical and mechanistic rationale supporting the combination of the two drugs to potentially provide greater benefit for patients with KRASG12C mutant NSCLC and other cancers," said Neil Desai, Ph.D., founder, president and chief executive officer, Aadi Bioscience, Inc. "We look forward to working closely with our Mirati counterparts to bring this treatment to those in need."

Under the terms of the collaboration agreement, Mirati will be responsible for sponsoring and operating the Phase 1/2 study, and jointly with Aadi, will oversee and share the cost of the study.

About Adagrasib (MRTX849)
Adagrasib is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C mutated cancers, as the KRASG12C protein regenerates every 24-48 hours. Studies of adagrasib have shown that the drug has a long half-life, extensive tissue distribution and is well tolerated. Adagrasib has also shown, in clinical trials, CNS penetrance and single-agent responses in non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and other solid tumors with KRASG12C mutations. Adagrasib is being evaluated in several clinical trials in combination with other anti-cancer therapies with strong scientific rationale in patients with advanced solid tumors. Registration-enabling studies are ongoing in NSCLC and colorectal cancer. For more information visit Mirati.com/science.

About nab-sirolimus
Nab-sirolimus is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is currently being evaluated in a tumor-agnostic registration-directed trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. In November 2021, nab-sirolimus was approved by the U.S. Food and Drug Administration (FDA) as FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).